Fig. 1: Overview of enrollment into the different dose levels and phases of the study.

The study consisted of two parts: a phase 1 dose escalation portion and a phase 1b dose expansion cohost at the recommended dose. This graph details the patients enrolled on each dose level (5, 10, 20 and 50 mg after protocol amendment) and phase (dose escalation and dose expansions) of the clinical trial. A total of 25 patients were treated.